
    
      Open, uncontrolled, multicenter, phase II study

      This study will enroll previous chemo-naïve patients with locally advanced unresectable or
      metastatic pancreatic cancer.

      Study regimen:

        -  Erlotinib 100 mg po qd daily AND

        -  Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on
           Day 1

        -  Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2
           weeks

      Each two weeks is a cycle. If at end of 12 cycles response continues, will administer
      Gemcitabine and erlotinib until progression.
    
  